Skip NavigationSkip to Content

NCI at Frederick Scientific Publications Advanced Search

Search

  1. NCI-F Publications

  2. Return to Quick Search
Search
  2. Year Published:

Your search returned 18 results.
User Information
Export Records
  1. 1.   A Single-Arm, Open-Label Phase II Study of ONC201 in Recurrent/Refractory Metastatic Breast Cancer and Advanced Endometrial Carcinoma
  2. Atkins, Sarah L P; Greer, Yoshimi Endo; Jenkins, Sarah; Gatti-Mays, Margaret E; Houston, Nicole; Lee, Sunmin; Lee, Min-Jung; Rastogi, Shraddha; Sato, Nahoko; Burks,Christina; Annunziata, Christina M; Lee, Jung-Min; Nagashima, Kunio; Trepel, Jane B; Lipkowitz, Stanley; Zimmer, Alexandra S
  3. The Oncologist. 2023, Jun 05;
  1. 2.   Phase I/II study of PexaVec in combination with immune checkpoint inhibition in refractory metastatic colorectal cancer
  2. Monge, Cecilia; Xie, Changqing; Myojin, Yuta; Coffman, Kelley; Hrones, Donna Mabry; Wang, Sophie; Hernandez, Jonathan M; Wood, Bradford J; Levy, Elliot B; Juburi, Israa; Hewitt, Stephen M; Kleiner, David E; Steinberg, Seth M; Figg, William D; Redd, Bernadette; Homan,Philip; Cam, Maggie; Ruf, Benjamin; Duffy, Austin G; Greten, Tim F
  3. Journal for Immunotherapy of Cancer. 2023, Feb; 11(2):
  1. 3.   A phase 1 and pharmacodynamic study of chronically-dosed, single-agent veliparib (ABT-888) in patients with BRCA1- or BRCA2-mutated cancer or platinum-refractory ovarian or triple-negative breast cancer
  2. Manzo, Julia; Puhalla, Shannon; Pahuja, Shalu; Ding, Fei; Lin, Yan; Appleman, Leonard; Tawbi, Hussein; Stoller, Ronald; Lee, James J; Diergaarde, Brenda; Kiesel, Brian F; Yu, Jing; Tan, Antoinette R; Belani, Chandra P; Chew, Helen; Garcia, Agustin A; Morgan, Robert J; Wahner Hendrickson, Andrea E; Visscher, Daniel W; Hurley, Rachel M; Kaufmann, Scott H; Swisher, Elizabeth M; Oesterreich, Steffi; Katz, Tiffany; Ji,Jay; Zhang, Yiping; Parchment, Ralph E; Chen, Alice; Duan, Wenrui; Giranda, Vincent; Shepherd, Stacie P; Ivy, S Percy; Chu, Edward; Beumer, Jan H
  3. Cancer Chemotherapy and Pharmacology. 2022, Apr 18; 89(5): 721-735.
  1. 4.   Establishing proof of mechanism: Assessing target modulation in early-phase clinical trials
  2. Kummar, S.; Do, K.; Coyne, G. O.; Chen, A.; Ji, J.; Rubinstein, L.; Doroshow, J. H.
  3. Seminars in Oncology. 2016, Aug; 43(4): 446-52.
  1. 5.   The split personality of NKT cells in malignancy, autoimmune and allergic disorders
  2. Subleski, J. J.; Jiang, Q.; Weiss, J. M.; Wiltrout, R. H.
  3. Immunotherapy. 2011, Oct; 3(10): 1167-1184.
  1. 6.   RanBPM is essential for mouse spermatogenesis and oogenesis
  2. Puverel, S.; Barrick, C.; Dolci, S.; Coppola, V.; Tessarollo, L.
  3. Development. 2011, Jun; 138(12): 2511-2521.
  1. 7.   Phase I trial of vandetanib and bevacizumab evaluating the VEGF and EGF signal transduction pathways in adults with solid tumours and lymphomas
  2. Kummar, S.; Gutierrez, M. E.; Chen, A.; Turkbey, I. B.; Allen, D.; Horneffer, Y. R.; Juwara, L.; Cao, L.; Yu, Y. K.; Kim, Y. S.; Trepel, J.; Chen, H.; Choyke, P.; Melillo, G.; Murgo, A. J.; Collins, J.; Doroshow, J. H.
  3. European Journal of Cancer. 2011, May; 47(7): 997-1005.
  1. 8.   Phase I trial of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), a heat shock protein inhibitor, administered twice weekly in patients with advanced malignancies
  2. Kummar, S.; Gutierrez, M. E.; Gardner, E. R.; Chen, X. H.; Figg, W. D.; Zajac-Kaye, M.; Chen, M.; Steinberg, S. M.; Muir, C. A.; Yancey, M. A.; Horneffer, Y. R.; Juwara, L.; Melillo, G.; Ivy, S. P.; Merino, M.; Neckers, L.; Steeg, P. S.; Conley, B. A.; Giaccone, G.; Doroshow, J. H.; Murgo, A. J.
  3. European Journal of Cancer. 2010, Jan; 46(2): 340-347.
  1. 9.   Phase I trial of temozolomide plus O-6-benzylguanine for patients with recurrent or progressive malignant glioma
  2. Quinn, J. A.; Desjardins, A.; Weingart, J.; Brem, H.; Dolan, M. E.; Delaney, S. M.; Vredenburgh, J.; Rich, J.; Friedman, A. H.; Reardon, D. A.; Sampson, J. H.; Pegg, A. E.; Moschel, R. C.; Birch, R.; McLendon, R. E.; Provenzale, J. M.; Gururangan, S.; Dancey, J. E.; Maxwell, J.; Tourt-Uhlig, S.; Herndon, J. E.; Bigner, D. D.; Friedman, H. S.
  3. Journal of Clinical Oncology. 2005, OCT 1; 23(28): 7178-7187.
  1. 10.   Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma
  2. Ryan, Q. C.; Headlee, D.; Acharya, M.; Sparreboom, A.; Trepel, J. B.; Ye, J.; Figg, W. D.; Hwang, K.; Chung, E. J.; Murgo, A.; Melillo, G.; Elsayed, Y.; Monga, M.; Kalnitskiy, M.; Zwiebel, J.; Sausville, E. A.
  3. Journal of Clinical Oncology. 2005, JUN 10; 23(17): 3912-3922.
  1. 11.   Genetics of ATP-binding cassette transporters
  2. Dean, M.
  3. Phase II Conjugation Enzymes and Transport Systems. 2005; 400 : 409-429.
  1. 12.   7-hydroxystaurosporine (UCN-01) inhibition of Akt Thr(308) but not Ser(473) phosphorylation: A basis for decreased insulin-stimulated glucose transport
  2. Kondapaka, S. B.; Zarnowski, M. J.; Yver, D. R.; Sausville, E. A.; Cushman, S. W.
  3. Clinical Cancer Research. 2004, NOV 1; 10(21): 7192-7198.
  1. 13.   SJG-136 (NSC 694501), a novel rationally designed DNA minor groove interstrand cross-linking agent with potent and broad spectrum antitumor activity. Part 2: Efficacy evaluations
  2. Alley, M. C.; Hollingshead, M. G.; Pacula-Cox, C. M.; W, W. R.; Hartley, J. A.; Howard, P. W.; Gregson, S. J.; Thurston, D. E.; Sausville, E. A.
  3. Cancer Research. 2004, SEP 15; 64(18): 6700-6706.
  1. 14.   Disruption of spermatogenesis in mice lacking A-type lamins
  2. Alsheimer, M.; Liebe, B.; Sewell, L.; Stewart, C. L.; Scherthan, H.; Benavente, R.
  3. Journal of Cell Science. 2004 117(7): 1173-1178.
  1. 15.   BRCA2 deficiency in mice leads to meiotic impairment and infertility
  2. Sharan, S. K.; Pyle, A.; Coppola, V.; Babus, J.; Swaminathan, S.; Benedict, J.; Swing, D.; Martin, B. K.; Tessarollo, L.; Evans, J. P.; Flaws, J. A.; H, el
  3. Development. 2004 131(1): 131-142.
  1. 16.   Correlation between reduction in plasma HIV-1 RNA concentration 1 week after start of antiretroviral treatment and longer-term efficacy
  2. Polis, M. A.; Sidorov, I. A.; Yoder, C.; Jankelevich, S.; Metcalf, J.; Mueller, B. U.; Dimitrov, M. A.; Pizzo, P.; Yarchoan, R.; Dimitrov, D. S.
  3. Lancet. 2001 358(9295): 1760-1765.
  1. 17.   Atm deficiency results in severe meiotic disruption as early as leptonema of prophase I
  2. Barlow, C.; Liyanage, M.; Moens, P. B.; Tarsounas, M.; Nagashima, K.; Brown, K.; Rottinghaus, S.; Jackson, S. P.; Tagle, D.; Ried, T.; Wynshaw-Boris, A.
  3. Development. 1998 125(20): 4007-4017.
  1. 18.   Immunoelectron Microscopy for Visualization of Nanoparticles
  2. Anderson, Sarah R; Parmiter, David; Baxa, Ulrich; Nagashima, Kunio
  3. Methods in molecular biology (Clifton, N.J.). 2018 1682: 65-71.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel